SAN DIEGO, Calif., Oct. 29 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. , a biopharmaceutical company focused on the treatment of obesity, will announce its financial results for the third quarter ended September 30, 2009 on Wednesday, November 4, 2009 after the markets close. The announcement will be followed by a live webcast and conference call at 5:00 p.m. Eastern time.
About Orexigen Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies that offer multiple approaches to treating obesity. The Company's lead investigational product, Contrave(R), has completed the COR Phase 3 clinical development program and is on track for a regulatory submission with the FDA in the first half of 2010. The Company's second obesity drug candidate, Empatic(TM), has completed Phase 2 trials. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approaches. Further information about the Company can be found at http://www.Orexigen.com.
CONTACT: Graham Cooper, Chief Financial Officer of Orexigen Therapeutics,
Inc., +1-858-875-8600; or Media, Lori Rosen of WeissComm Partners,
+1-212-301-7173, for Orexigen Therapeutics, Inc.
Web site: http://www.Orexigen.com/
